Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

42
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
42
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

897
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
897
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

496
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
496
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

337
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
337
Hepatic Portal System01:21

Hepatic Portal System

8.0K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
8.0K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

257
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
257

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An unusual gastric mass in a patient with human immunodeficiency virus infection.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026
Same author

Response to the Letter Regarding "Efficacy and Safety of Hypofractionated Radiation Therapy Combined With Immunotherapy for Hepatocellular Carcinoma With Vp4 Portal Vein Tumor Thrombosis".

Hepatology research : the official journal of the Japan Society of Hepatology·2026
Same author

Clinical characteristics of synchronous and metachronous superficial esophageal squamous cell carcinoma during surveillance after endoscopic submucosal dissection.

Surgical endoscopy·2026
Same author

Improved hypopharyngeal visibility and early cancer detection using the modified Killian method during esophagogastroduodenoscopy in patients at high risk of head and neck cancer.

Esophagus : official journal of the Japan Esophageal Society·2026
Same author

Safety of Argon Plasma Coagulation for Minute Synchronous Neoplasms Detected under General Anesthesia during Endoscopic Laryngopharyngeal Surgery: A Case Series.

Case reports in gastroenterology·2026
Same author

Treatment outcomes of low-radial-force self-expandable metal stent placement and palliative radiotherapy for unresectable advanced esophageal squamous cell carcinoma with dysphagia.

Esophagus : official journal of the Japan Esophageal Society·2026

Related Experiment Video

Updated: Apr 7, 2026

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

20.0K

Adiponectin in chronic hepatitis C.

Toru Arano1, Hayato Nakagawa2, Hitoshi Ikeda3

  • 1Department of Gastroenterology, Toshiba General Hospital, 6-3-22 Higashi-ooi, Shinagawa-ku, Tokyo, 140-8522, Japan. toru.arano@toshiba.co.jp.

Clinical Journal of Gastroenterology
|July 17, 2015
PubMed
Summary
This summary is machine-generated.

Low levels of adiponectin, an important hormone from fat tissue, are linked to obesity complications and liver disease. This summary explores adiponectin's potential role in chronic hepatitis C, a metabolic liver condition.

Keywords:
AdiponectinChronic hepatitis CHepatocellular carcinoma

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.8K
"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.3K

Related Experiment Videos

Last Updated: Apr 7, 2026

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

20.0K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.8K
"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.3K

Area of Science:

  • Endocrinology
  • Hepatology
  • Metabolic Diseases

Background:

  • White adipose tissue functions as an endocrine organ secreting adipokines.
  • Adiponectin, a key adipokine, has anti-inflammatory and insulin-sensitizing effects, with levels decreasing in obesity.
  • Low adiponectin (hypoadiponectinemia) is associated with obesity comorbidities and liver pathologies like steatosis and fibrosis.

Purpose of the Study:

  • To summarize evidence for adiponectin's role in chronic hepatitis C (CHC).
  • To explore the connection between adipokines, viral infection, and metabolic disturbances in CHC.
  • To highlight CHC as a metabolic liver disease with features of insulin resistance, inflammation, steatosis, and fibrosis.

Main Methods:

  • Review of existing data and literature on adiponectin and CHC.
  • Analysis of studies investigating hypoadiponectinemia in relation to liver disease.
  • Examination of the interplay between viral hepatitis and metabolic factors.

Main Results:

  • Hypoadiponectinemia is implicated in hepatic steatosis, inflammation, and fibrosis.
  • CHC exhibits characteristics of both a viral and a metabolic liver disease.
  • Adipokines may bridge the link between CHC viral infection and metabolic derangements.

Conclusions:

  • Adiponectin plays a significant role in metabolic regulation and liver health.
  • Low adiponectin levels may contribute to the pathogenesis of CHC.
  • Further research is warranted to elucidate adiponectin's specific functions in CHC.